Clicky

Halozyme Therapeutics Inc(RV7)

Description: Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.


Keywords: Biotechnology Biopharmaceutical Solid Tumors Immunology Antibodies Breast Cancer Monoclonal Antibodies Antineoplastic Drugs Multiple Sclerosis Multiple Myeloma HIV Orphan Drug Amyloidosis Chronic Lymphocytic Leukemia Testosterone Treatment Of Hiv Epinephrine Nivolumab Allergic Reactions Testosterone Replacement Therapy Treatment Of Chronic Lymphocytic Leukemia Hyaluronidase Severe Active Rheumatoid Arthritis Herceptin Hylenex Severe Autoimmune Diseases Teriparatide

Home Page: halozyme.com

12390 El Camino Real
San Diego, CA 92130
United States
Phone: 858 794 8889


Officers

Name Title
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. President, CEO & Director
Ms. Nicole LaBrosse CPA Senior VP & CFO
Dr. Michael J. LaBarre Ph.D. Senior VP & CTO
Mr. Mark Snyder Esq. Senior VP & Chief Legal Officer
Ms. Cortney Caudill M.B.A. Chief Operations Officer
Ms. Tram Bui Head of Investor Relations & Corporate Communications
Ms. Amy Marinne Fox Chief Human Resources Officer
Mr. Gary Grote Chief Commercial Officer
Dr. Christopher Wahl M.B.A., M.D. Chief Business Officer
Dr. Charles P. Theuer M.D., Ph.D. Chief Medical Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 10.989
Trailing PE: 15.8737
Price-to-Book MRQ: 13.4584
Price-to-Sales TTM: 6.1399
IPO Date:
Fiscal Year End: December
Full Time Employees: 373
Back to stocks